Expect sharp downside pressure as guidance cuts confirm deteriorating demand and execution. Monitor the May 6 earnings call for details on cost actions and B Medical sale timeline. The lack of buyback execution despite authorization suggests management priorities elsewhere.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 6 $18.38entry
- T+1 · 6mo ago +1.03%α +1.36% · $18.57
- T+5 · 6mo ago −4.62%α −5.76% · $17.53
- T+20 · 6mo ago +29.98%α +27.20% · $23.89
- T+60 · 4mo ago +53.05%α +50.99% · $28.13
Price Chart
How similar events traded
Executive Summary
Azenta reported Q2 FY2026 revenue of $145M (+1% reported, -3% organic), non-GAAP EPS of ($0.04) vs $0.01 a year ago, and a $149M goodwill impairment. FY2026 guidance was sharply cut: organic revenue now expected -2% to +1% (prior 3-5% growth) and Adjusted EBITDA margin expected -125bps to flat (prior +300bps expansion). Long-range plan extended to 2029, and B Medical Systems sale remains uncertain. The filing signals worsening demand and execution issues.
Key Financial Metrics
Key Facts
- Q2 FY2026 revenue: $145M, up 1% YoY reported, organic down 3%
- GAAP diluted EPS from continuing ops: ($3.41) vs ($0.43) YoY, including $149M goodwill impairment
- Non-GAAP diluted EPS: ($0.04) vs $0.01 YoY
- FY2026 organic revenue guidance lowered to -2% to +1% from prior 3-5% growth
- FY2026 Adjusted EBITDA margin outlook cut to -125bps to flat from prior +300bps expansion
- Long-range plan extended from 2028 to 2029
- B Medical Systems sale delayed; buyer has not secured financing
- No share repurchases executed under $250M program
Financial Impact
Goodwill impairment of $149M; guidance revision implies $30-40M revenue reduction vs prior outlook
Risk Factors
- Further demand weakening in life sciences tools market
- B Medical Systems sale falling through, requiring additional cash outflows or write-downs
- Additional impairment charges if revenue trends continue declining
- Dilution from potential equity offering if cash needs arise
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-030677 |
| Document: azta-20260505.htm | 0001628280-26-030677 |
| Document: 0001628280-26-030677-index-headers.html | 0001628280-26-030677 |
| Document: 0001628280-26-030677-index.html | 0001628280-26-030677 |
| Document: 0001628280-26-030677.txt | 0001628280-26-030677 |
| 8-K Data (Synthetic) | 0001628280-26-030677 |
Track record
12 reports on AZTA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago 8-K Bullish 6/10 Entry $48.90 Now $47.22 −3.44% settles Nov 18
- Oct 30, 202617d ago 8-K Neutral 4/10 Entry $39.06 to $39.16 Now $47.22 +20.89% ▲ +0.26% +2.96% vs SPY
- Oct 30, 202617d ago Press Release Neutral 4/10 Entry $39.06 to $39.16 Now $47.22 +20.89% ▲ +0.26% +2.96% vs SPY
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $35.89 to $37.18 Now $47.22 −31.57% ▼ −3.59% −4.57% vs SPY
- Sep 17, 20268w ago 8-K Neutral 2/10 Entry $33.63 to $34.20 Now $47.22 +40.41% ▲ +1.69% +1.09% vs SPY
- Sep 4, 202610w ago 8-K Neutral 4/10 Entry $31.33 to $32.04 Now $47.22 +50.72% ▲ +2.27% +3.48% vs SPY
- Aug 24, 202612w ago 8-K Neutral 4/10 Entry $32.88 to $32.65 Now $47.22 +43.61% ▼ −0.70% −1.17% vs SPY
- Aug 8, 202614w ago Institutional Cluster Mixed 5/10 Entry $33.33 to $33.58 Now $47.22 +41.67% ▲ +0.75% +0.80% vs SPY
- Aug 4, 202614w ago Press Release Bullish 7/10 Entry $31.82 to $33.53 Now $47.22 +48.40% ▲ +5.37% +5.02% vs SPY
- Jul 8, 202618w ago 8-K Mixed 5/10 Entry $24.51 to $25.44 Now $47.22 +92.66% ▲ +3.79% +2.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers